These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 29683727)
1. Bone turnover markers and novel biomarkers in lung cancer bone metastases. Lang J; Zhao Q; He Y; Yu X Biomarkers; 2018 Sep; 23(6):518-526. PubMed ID: 29683727 [TBL] [Abstract][Full Text] [Related]
2. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer. Huang J; Gu T; Ying J Int J Clin Oncol; 2017 Dec; 22(6):1015-1025. PubMed ID: 28677013 [TBL] [Abstract][Full Text] [Related]
3. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A Clin Chem; 1999 Aug; 45(8 Pt 1):1240-7. PubMed ID: 10430790 [TBL] [Abstract][Full Text] [Related]
4. Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation. Chu T; Teng J; Jiang L; Zhong H; Han B Biochem Biophys Res Commun; 2014 Jan; 443(3):962-8. PubMed ID: 24361889 [TBL] [Abstract][Full Text] [Related]
5. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Ebert W; Muley T; Herb KP; Schmidt-Gayk H Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Mountzios G; Ramfidis V; Terpos E; Syrigos KN Clin Lung Cancer; 2011 Nov; 12(6):341-9. PubMed ID: 21703936 [TBL] [Abstract][Full Text] [Related]
8. [Correlation of the levels of the bone turnover markers BAP and β-CTX with bone metastasis progress in lung cancer patients]. Tang Q; Zhao H; Jia R; Liu L Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):144-7. PubMed ID: 23514943 [TBL] [Abstract][Full Text] [Related]
9. ICTP in bone metastases of lung cancer. Franjević A; Pavićević R; Bubanović G Coll Antropol; 2011 Mar; 35(1):43-7. PubMed ID: 21661353 [TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470 [TBL] [Abstract][Full Text] [Related]
11. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases. Zulauf N; Brüggmann D; Groneberg D; Oremek GM Oncology; 2019; 97(4):236-244. PubMed ID: 31412345 [TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of bone metabolism in breast cancer. Lyubimova NV; Kozharskaya GV; Portnoi SM; Kushlinskii NE Bull Exp Biol Med; 2014 Oct; 157(6):769-72. PubMed ID: 25342482 [TBL] [Abstract][Full Text] [Related]
13. MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment. Zhao Q; Li P; Ma J; Yu X Recent Pat Anticancer Drug Discov; 2015; 10(2):182-200. PubMed ID: 25600282 [TBL] [Abstract][Full Text] [Related]
14. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Chung JH; Park MS; Kim YS; Chang J; Kim JH; Kim SK; Kim SK Yonsei Med J; 2005 Jun; 46(3):388-93. PubMed ID: 15988811 [TBL] [Abstract][Full Text] [Related]
16. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C J BUON; 2009; 14(3):463-72. PubMed ID: 19810140 [TBL] [Abstract][Full Text] [Related]
17. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures. Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373 [TBL] [Abstract][Full Text] [Related]
18. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results. Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213 [TBL] [Abstract][Full Text] [Related]
20. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Bombardieri E; Martinetti A; Miceli R; Mariani L; Castellani MR; Seregni E Eur J Nucl Med; 1997 Nov; 24(11):1349-55. PubMed ID: 9371866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]